Genmab — November 2019
-
a saw from this message from a Belgian University hospital that one of the area's BMS-986253 is used is Dermatological tumors/ melanoma https://www.uzgent.be/nl/zorgaanbod/mdspecialismen/Geneesmiddelenonderzoek/Lopende-studies/Paginas/Indicatoren-dermatologische-tumoren.aspx (clinicaltrials only mentioned 'advanced cancers' https://www.clinicaltrials.gov/ct2/show/study/NCT03400332?term=BMS-986253&show_locs=Y#locn )
-
Så er de vist oppe igen. Kursen hoppede lige.
-
Har de fået deres system fra den samme leverandør som Skat?
-
Pefekt. Så kan de lige smide IC4 togene med ind i erstatningskravet. Rart at have det hele samlet et sted
-
Nadaq forklarer og undskylder.
https://www.proinvestor.com/investornyt/646804/nasdaq-toppen-efter-borskaoset-vill-be-om-ursakt -
-
Marshall Wace LLP has reduced his short position to 323390 shares issued by Genmab A/S https://oasm.dfsa.dk/uk/showannouncement.aspx?aid=969f9eaf-a0ab-4077-992d-50aa684aa216
-
Der er en sjat endnu.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind